Long Non-Coding RNAs in Lung Cancer: The Role in Tumor Microenvironment

Shuang Dai1†, Ting Liu2†, Yan-Yang Liu1†, Yingying He3, Tao Liu4, Zihan Xu1†, Zhi-Wu Wang5* and Feng Luo1*

1Department of Medical Oncology, Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 2Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 3Oncology Department, People’s Hospital of Deyang City, Deyang, China, 4Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu Medical College, Chengdu, China, 5Department of Chemoradiotherapy, Tangshan People’s Hospital, Tangshan, China

The development of various therapeutic interventions, particularly immune checkpoint inhibitor therapy, have effectively induced tumor remission for patients with advanced lung cancer. However, few cancer patients can obtain significant and long-lasting therapeutic effects for the limitation of immunological nonresponse and resistance. For this case, it’s urgent to identify new biomarkers and develop therapeutic targets for future immunotherapy. Over the past decades, tumor microenvironment (TME)-related long non-coding RNAs (lncRNAs) have gradually become well known to us. A large number of existing studies have indicated that TME-related lncRNAs are one of the major factors to realize precise diagnosis and treatment of lung cancer. Herein, this paper discusses the roles of lncRNAs in TME, and the potential application of lncRNAs as biomarkers or therapeutic targets for immunotherapy in lung cancer.

Keywords: lncRNA, non-small cell lung cancer, immunotherapy, tumor microenvironment, biomarker

INTRODUCTION

Lung cancer ranks the most important leading cause of cancer-related deaths globally (Bray et al., 2018; Nasim et al., 2019). Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers (Bender, 2014). Despite the improvements of NSCLC treatment in traditional therapies, the overall cure and survival rates for NSCLC remain low, particularly in metastatic diseases (Siegel et al., 2020). Existing research suggests that combination treatment options (using immunotherapies or targeted therapies) may be the ultimate curative option. Hence, it is quite essential to investigate the precise molecular mechanism and biomarkers to promote the effectiveness of treatment, especially immune checkpoint inhibitors (ICIs).

ICIs reactivate dysfunctional and/or exhausted T cells by targeting immune checkpoints including cytotoxic T lymphocyte related protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its ligand, PD-L1. To date, ICIs have altered treatment paradigm in multiple indications such as...
melanoma, NSCLC, renal cell carcinoma (RCC) and so on (Pardoll, 2012; Hoos, 2016; Papaioannou et al., 2016; Munn and Jain, 2019; Xin Yu et al., 2019). However, the treatment response of ICIs remains unsatisfactory, and the objective response rate (ORR) for ICIs alone is only about 15–25%, and even lower in pancreatic carcinoma, triple negative breast cancer, and colorectal cancer with microsatellite stability (MSS) (Gao et al., 2019). Most patients still face the dilemmas of primary/acquired resistance of ICIs. A great number of studies have investigated the resistance mechanisms that limit the efficacy of ICIs such as disability of neoantigen presentation, activation of T cell, the impaired formation of T cell memory and the dysregulation of tumor microenvironment (TME) (Gajewski et al., 2013; Hegde et al., 2016; Jenkins et al., 2018; Yi et al., 2019; Schoenfeld and Hellmann, 2020). TME, comprised of the interaction between tumor cells, tumor-associated stromal cells as well as extracellular matrix, has been considered to be of great significance in activating the effect of ICIs. Notably, identifying abnormal TME and treatment-related biomarkers are not only the important means of antitumor therapy, but also of immune efficiency improvement (Gao et al., 2019).

LncRNAs, the most frequently expressed nonprotein-coding RNAs, have at least 200 nucleotides and are usually located in the cell nucleus, cytoplasm and exosomes where they interact with various molecules like DNA, RNA, proteins and so forth (Atianand and Fitzgerald, 2014). Multiple pathophysiological processes through the epigenetic, transcriptional and post-transcriptional regulation of gene are regulated by lncRNAs, of which lncRNAs include at least five categories including intergenic lncRNAs, intronic lncRNAs, antisense lncRNAs, sense lncRNAs and bidirectional lncRNAs (pseudogenes and retrotransposons) (Rinn and Chang, 2012). In TME, lncRNAs can directly or indirectly affect the growth of tumor cells, and play a nonnegligible role in the regulatory recircuit of the immune cells, promoting recruitment of immunosuppressive cells such as Tregs, M2-type macrophages and myeloid-derived suppressor cells (MDSCs), down-regulating the expression of adhesion molecules on endothelial cells, as well as up-regulating of immune checkpoints (PD-1/PD-L1 and CTLA4), which could contribute to tumor development and resistance to drugs or radiotherapy (Fu et al., 2021; Taheri et al., 2021). Specifically, lncRNAs are new emerging therapeutic targets and important prognostic biomarkers in multiple cancers including lung cancer.

FIGURE 1 | Interaction of lncRNAs with tumor microenvironment (TME) regulating lung cancer development.
Accumulating studies have identified that lncRNAs are essential mediators of intercellular communication between tumor and stromal cells in local and distant microenvironment of lung cancer.

In this review, we focus on describing how lncRNAs derived from tumor cells, immune cells or exosomes regulate the TME in lung cancer to promote tumor progression, emphasizing the role of these lncRNAs in tumor cells, lymphoid immune cells, macrophages, cancer-related fibroblasts, tumor vasculature and other components of TME (Figure 1).

### LNCRNAS AFFECT LYMPHOID IMMUNE CELLS

Existing research has reported that lymphoid immune cells within tumors have two-sided (positive and negative) effects on tumorigenesis and tumor progression (Joyce and Pollard, 2009). LncRNAs as important regulator molecules influence the activity and sensitivity of tumor-infiltrating T cells. Duan et al. conducted lncRNA profiling to screen for differentially expressed lncRNAs related to CD8⁺ T cells and activated memory CD4⁺ T cells in NSCLC (Duan et al., 2020). A total of 90 DElncRNAs (differential expression lncRNA) showed different expression patterns in CD8⁺ T immune cells, and 48 DElncRNAs were associated with activated memory CD4⁺ T cells. The enrichment pathway analyses revealed that differentially expressed lncRNAs were mainly involved in cytokine–cytokine receptor interaction as well as viral protein interaction with cytokine–cytokine receptor, suggesting that T cell-specific lncRNAs mediated an immune response during NSCLC progression. This study provided a cursory but comprehensive indication of the vital role of lncRNAs in influencing the biological function of T lymphoid cells in lung cancer. Specifically, a study reported that a large proportion of CTLs/Th1 cells underwent apoptosis in NSCLC, a process that could be further facilitated by anti-CD3, while the proportion of Th2 cells/Treg cells were relatively low in TME, suggesting CTLs/Th1 cells were more sensitive to activation-induced cell death (AICD) than Tregs/Th2 cells. Further analysis indicated that STAT1-mediated transcription of NKILA caused AICD of CTLs/Th1 cells by suppressing NF-κB which was upregulated in Tregs/Th2 cells compared with CTLs/Th1 cells (Huang et al., 2018). Tang et al. also observed that the proportion of Th2 was high in peripheral blood of NSCLC, and the proportion of CTLs/Th1 cell was lower than that in normal control. LncRNA NEAT1 was also reported to be upregulated in lung cancer tissues with high TILs. NEAT1 negatively regulated CD8⁺ T cells in lung cancer cells via increasing CXCL10, CCL5, and IFN-β expression, which directly induced cGAS/STING Signaling, to suppress immune response (Ma et al., 2020). In addition, signaling from SOX2-OT/miR-30d-5p/PDK1 contributed to apoptosis of CD8⁺ T cells, which in turn promoted immune escape of NSCLC (Chen et al., 2021). The direct interaction between SChLAP1 and AUFI antagonized the binding between AUFI and PD-L1 mRNA 3′-UTR, resulting in improving PD-L1 mRNA stability and expression, thereby attenuating CTLs function (Du et al., 2021). Collectively, lncRNAs control lung cancer development and metastasis by affecting T cell function in TME, and targeting lncRNA may alter the activity of CTLs, thereby enhancing the effectiveness of immunotherapy.

### LNCRNAS IN CANCER STEM CELLS

Cancer stem cells (CSCs) are regarded as a population of tumor cells characterized by abilities to self-renew or to differentiate into cancer non-stem progenies, and therefore often involved in the resistance to cancer therapies, tumorigenesis, epithelial-to-mesenchymal transition (EMT) and tumor metastases (Clarke and Fuller, 2006; Zhao, 2016). CD44, CD133, OCT-4, Bmi-1, ALDH1, ABCG2 and KLF4 are common CSC biomarkers that are specifically and highly expressed on the cell surface. For example, Prior researches elucidated the determinants about the resistance to cancer treatments including growth features associated with slow division and quiescence (Vidal et al., 2014; Ajani et al., 2015), ATP-binding cassette (ABC) transporters expression levels involved in elimination of drugs (Abdullah and Chow, 2013), and the presence of increased detoxification of endogenous and exogenous aldehyde substrates via the aid of aldehyde dehydrogenases (ALDHs) (Sládek, 2003; Ahmed Laskar and Younus, 2019). As a pivotal component of the TME, the maintenance of CSCs as well as the growth and progression of tumors are inseparable from the cancer microenvironment, together with various regulatory factors. To date, lncRNAs involved in both CSCs biological functions and cancer development have received considerable research attention (Schwerdtfeger et al., 2021). Here we have reviewed relevant literatures to summarize the functions.

In regulating tumorigenesis, lncRNA HOTAIR was reported to exert pro-cancer effects by inducing CSCs and EMT formation under the direct regulation of STAT3 under cigarette smoke exposure (Liu et al., 2015). The relationship between stemness and EMT programs has been reviewed in previous literature (Wilson et al., 2020). DUXAP10 was obviously upregulated in Cd-induced lung cancer cells. DUXAP10 knockdown induced the stemness markers including KLF4, KLF5 and Nanog downregulation, weakened the capacity of spheres formation and reduced the number of stem cells marked by CD133 via inhibiting the Hedgehog signaling pathway signal, which was involved in Cd carcinogenesis in lung cells (Lin et al., 2021). As for resistance to cancer therapies, Liu et al. revealed that lncRNA HOTAI could cause cisplatin resistance via inducing stem cell-related biomarkers β-catenin and KLF4, especially directly regulating KLF4, to promote stemness (Liu et al., 2016). Similarly, LINCO1224 is obviously upregulated in NSCCL cells and associated with NSCCL radioresistance. LINCO1224 knockdown dramatically promotes the abilities of self-renew by regulating the expression of ZNF91 and therefore suppresses the irradiation sensitivity of NSCCL (Fu et al., 2021). In terms of EMT and metastasis, FOXF1-AS1 acted as a protective factor and interacted with PRC2 components EZH2 to hinder self-renewal of NSCCL CSCs and reduce the number of stem-like cells, thus leading to impaired EMT capacity of tumor cells (Miao et al.,
LncTCF7 overexpression increased NSCLC sphere formation and expression of specific markers (EpCAM, Sox2, Oct4 and Nanog). Further study of the molecular mechanism of TCF7 regulation of CSC revealed that TCF7 may exhibit oncogenic activity by regulating EpCAM via competitively binding miR-200c, which stimulated invasive activity and enhanced the self-renewal capacity of CSCs (Wu and Wang, 2017). The interaction with LINC00662 and its RNA binding protein Lin28 can elevate CSCs stemness and invasion ability of tumor cells, contributing to the poor prognosis of NSCLC (Gong et al., 2018). The expression of LINC01123 is up-regulated in LUAD. Mechanistically, LINC01123 could precipitate miR-449b-5p to release NOTCH1, thereby promoting downstream NOTCH1 signaling and resulting in accelerating LUAD cell stemness and EMT (Zhang et al., 2020). More LncRNAs affecting CSC properties are summarized in Table 1. Taken together, all these data elucidate that dysregulation of lncRNAs affects CSCs traits and tumor invasion, and could be potential targets of tumor immunotherapy.

### TABLE 1 | LncRNAs and their respective molecules or pathways involved in the TME.

| LncRNA          | Effects                  | Mechanism                                                                 | References                           |
|-----------------|--------------------------|---------------------------------------------------------------------------|--------------------------------------|
| FGD5-AS1        | M2                       | Regulating FGD5-AS1/miR-944/MACC1 axis                                     | Lv et al. (2021)                     |
| XIST            | M2                       | Regulates M2 polarization                                                  | Sun and Xu (2019)                    |
| GNAS-AS1        | M2                       | GNAS-AS1/miR-4319/NECAB3 axis                                              | Li et al. (2020a)                    |
| SOX2-OT         | CTLs/Th1                 | Targeting miR-627-3p/Smad signaling                                       | Zhou et al. (2021)                   |
| NkILA           | CTLs                     | Enhancing AICD of CTLs/Th1 cells by suppressing NF-κB                      | Huang et al. (2018)                  |
| NEAT1           | CTLs                     | Suppressing cGAS/STING Signaling                                          | Ma et al. (2020)                     |
| SOX2-OT         | CTLs                     | SOX2-OT/miR-30d-5p/PDK1                                                   | Chen et al. (2021)                   |
| SchlAP1         | CTLs                     | Regulating the AUF1/POL1 axis                                              | Du et al. (2021)                     |
| HOTAIR          | CSFs                     | Inducing EMT and CSCs under the direct regulation of STAT3                | Liu et al. (2015)                    |
| HOTAIR          | CSFs                     | Inducing CSCs-related biomarkers β-catenin and Klf4                        | Liu et al. (2016)                    |
| FOXF1-AS1       | CSFs                     | Interacting with EZH2 to inhibit the EMT ability of tumor cells           | Miao et al. (2016)                   |
| TCF7            | CSFs                     | Regulating TCF7/miR-200c/EpCAM                                            | Wu and Wang (2017)                   |
| LINC00662       | CSFs                     | Interacting with Lin28                                                    | Gong et al. (2018)                   |
| DUXAP10         | CSOs                     | Inhibiting the Hedgehog signaling pathway                                 | Lin et al. (2021)                    |
| MCF2L-AS1       | CSOs                     | Regulating miR-673-5p                                                     | Li and Lin (2021)                    |
| LINC01224       | CSOs                     | Interacting with ZNF91 to increase resistance                              | Fu et al. (2021)                     |
| LINC01123       | CSOs                     | Precipitating miR-449b-5p to activate NOTCH1 pathway signaling             | Zhang et al. (2020)                  |
| DANCOR          | CSOs                     | Activating DANCOR/miR-216a signaling                                       | Yu et al. (2020)                     |
| DHRS4-AS1       | CSOs                     | Modulating DHRS4-AS1/miR-224-3p signaling                                 | Yan et al. (2020)                    |
| MACC1-AS1       | CSOs                     | MACC1-AS1/1UPF1/LATS1/2 axis                                              | Wang et al. (2020)                   |
| loc107985872    | CSOs                     | Activating the notch1 signaling pathway                                    | Guo et al. (2020)                    |
| SNLCR1          | CSOs                     | Interacting with sPLA2                                                    | Xu et al. (2019)                     |
| LINC00887       | CSOs                     | Stimulating multiple microRNAs (miRNAs)                                  | Tien et al. (2019)                   |
| HNAD2-AS1       | CSOs                     | Interacting negatively with TGF-β1                                       | Miao et al. (2019)                   |
| TUSC-7          | CSOs                     | sponging miR-146                                                          | Huang et al. (2019)                  |
| CASCG11         | CSOs                     | Interacting with TGF-β1 to increase stemness of CSCs                      | Fu et al. (2019)                     |
| CCAT1           | CSOs                     | Activating Wnt signaling                                                  | Xu et al. (2018)                     |
| DGR5R           | CSOs                     | DGR5R/miR-330-5p/CD44 axis                                                | Wang et al. (2018)                   |
| NEAT1           | CSOs                     | Activating Wnt signaling                                                  | Jiang et al. (2018)                  |
| HOTAIRM1        | MDScs                    | Targeting HOXA1                                                          | Tian et al. (2018a)                  |
| RUNXOR          | MDScs                    | Regulating RUNX1 mRNA                                                     | Tian et al. (2018b)                  |
| LncRNA Ptx1     | MDScs                    | Attenuating Arg1 activity and ROS production                              | Zheng et al. (2019)                  |
| AK036398        | MDScs                    | Repressing Arg1 activity in vitro and CD244 expression                     | Tian et al. (2020)                   |
| MALAT1          | MDScs                    | Unknown                                                                   | Zhao et al. (2018)                   |
| LINC00301       | Tregs                    | Accumulating Tregs upon targeting TGF-β1                                  | Sun et al. (2020)                    |
| Csort64         | Tregs                    | Decreasing Tregs abundance                                                | Pang et al. (2021)                   |
| NRK             | CAFs                     | Unknown                                                                   | Wei et al. (2021)                    |
| LINC00173.v1    | Vasculature              | Sponging miR-511-5p as a ceRNA                                            | Chen et al. (2020)                   |
| EPIC1           | Vasculature              | Ang2 -TIE2 signaling pathway                                              | Hou et al. (2021)                    |
| LINC00667       | Vasculature              | Inducing eukaryotic translation initiation factor 4A3 (EIF4A3)            | Yang et al. (2020)                   |
| FB30028010Rik    | Vasculature              | Sponging miR-223-3p                                                       | Qin et al. (2020)                    |
| MCM3AP-AS1      | Vasculature              | Targeting miR-340-5p/KPNA4 axis                                           | Li et al. (2020b)                    |
| PVT1            | Vasculature              | Targeting the miR-29c/VEGF signaling pathway                              | Mao et al. (2019)                    |
| LINCO0312       | Vasculature              | Binding YBX1                                                              | Peng et al. (2018)                   |
| lnc-MMP2-2      | Vasculature              | Regulating MMP2 expression                                                | Wu et al. (2018)                     |

LncRNAs: Long Non-coding RNAs; CSCs: Cancer stem cells; MDSCs: Myeloid-derived suppressor cells; Tregs: Regulatory T cells; M2: alternatively activated macrophage.
Long Non-Coding RNAs in TME

Dai et al.

In recent years, it has been shown that lncRNAs originating from tumor cells are involved in the polarization of TAMs and result in tumor progression. Tumor cell-derived FGD5-AS1 via exosomes transportation promotes upregulation of M2 polarization markers (CD163, CD206, ARG1) and downregulation of M1 macrophage markers iNOS and IL-2 in NSCLC (Lv et al., 2021). Sun et al. summarized that the upregulated lncRNA XIST promoted macrophage conversion to M2 characterized by the deletion of specific makers like IL-10 and CD163, to affect tumor invasion and migration of lung cancer (Sun and Xu, 2019). GNAS-AS1 inhibits miR-4319 expression, and consequently activates N-terminal EF-hand calcium binding protein 3 (NECAB3) in THP-1-differentiated macrophages. Therefore, GNAS-AS1 increases the number of M2 macrophage and consequently promoting NSCLC cell growth and metastasis (Li Z. et al., 2020). Moreover, tumor-derived exosomal SOX2 overlapping transcript also play an important role in modulating the polarization of TAMs in NSCLC though regulating SOX2/miR-627-3p/Smds axis (Zhou et al., 2021). Taken together, lncRNAs directly or indirectly regulate the polarization of TAMs to affect lung cancer progression and metastasis, but the specific regulatory mechanism controlling the macrophages M2 polarization in lung cancer needs to be further studied.

**LNCRNAS PROMOTE BY REGULATING IMMUNE SUPPRESSIVE CELLS**

Studies have shown that the interactions between non-tumor cells exposed to the tumor microenvironment and tumor cells contribute to tumor progression and metastasis. In addition, T cells in tumors are often dysregulated and unable to generate specific responses to tumor cells in a timely manner. Immunosuppressive cells, including regulatory T cells (Tregs) usually expressing CD4, CD25 and FOXP3 markers (T cells that are not immunosuppressive) and MDSC, can contribute directly or indirectly to immunosuppression, which are reviewed in detail below.

**Myeloid-Derived Suppressor Cells**

Myeloid-derived suppressor cells (MDSCs) express two specific markers, CD11b and Gr1, and represent a heterogeneous population of myeloid origin that are activated and proliferated by growth factors and cytokines released by tumor cells. Once MDSCs are activated, they accumulate in lymphoid organs and tumors and exert immunosuppression on T cells. Currently, the cellular mechanisms by which MDSCs have been shown to be involved in immunosuppressive activity are: 1) inhibition of CTL cells activation and proliferation in an MHC-restricted or unrestricted and antigen-specific manner (Nagaraj et al., 2007; Zou et al., 2021); 2) indirectly affects T cell activation via the induction of Treg proliferation and benefiting from TGF, IL-10 production (Serafini et al., 2008); 3) Stimulus of macrophage conversion to M2 by secreting IL-10 and down-regulation of IL-12 that promotes M1 generation (Sinha et al., 2007); 4) interaction with type II INKT, which promotes tumor progression through IL-13 production, thereby inducing aggregation of MDSCs (Zou et al., 2021). Of note, MDSCs have immunosuppressive activity only when activated. The molecules that can activate MDSCs include two main categories: 1) tumor-derived soluble factor (TDSF), which inducing the proliferation of MDSCs though activating STAT3 to stimulate the proliferation of myeloid cells and inhibit the differentiation of mature myeloid cells, including VEGF, SCF, GM-CSF, G-CSF, IL-6, IL-10, IL-12, MMP9 and CCL2 (Talmadge, 2007; Marigo et al., 2008); 2) soluble factors released by activated T cells and tumor-derived stromal cells, such as IFN-γ, TLRs ligands, IL-4, IL-13 as well as TGF-β, are responsible for the activation of different transcription factors such as STAT6, STAT1 and NfYB (Gabrilovich and Nagaraj, 2009). Recently, it has been shown that lncRNAs affect lung cancer progression by regulating the immunosuppressive function of MDSCs in TME. Tian et al. discovered that HOTAIRM1 is obviously downregulated in MDSCs and its expression reduces in peripheral blood of lung cancer. Overexpression of HOTAIRM1 can positively target HOXA1 and induce subsequent reduction of the immunosuppression function of MDSCs, as well as increase the number of Th1/CD8+ cytotoxic T lymphocyte cells (CTLs), thereby sustaining improving the antitumor immune response (Tian et al., 2018a). Moreover, they also observed that the expression of lncRNA RUNXOR is higher in the blood of lung cancer patients than the levels in healthy samples, while decreases after surgery. Further detection suggested that RUNXOR can promote the activation of MDSCs and decrease the proportion of Th1/CTL cells by regulating RUNX1 mRNA expression (Tian et al., 2018b). A study on lncRNA MALAT1 indicated that MALAT1 directly affected MDSCs differentiation in lung cancer (Zhou et al., 2018). Some studies are more detailed. Zheng et al. identified that the expression level of lncRNA Pvt1 was upregulated in G-MDSCs following induction of IL-6 and GM-CSF. In contrast, when Pvt1 was knocked down, Arg1 activity and ROS production were...
significantly reduced and the ability of G-MDSCs to suppress T cells turned weak. In mice injected with Lewis lung carcinoma cells, they found that the number of CTLs/Th1 cells increased compared with the normal treatment group. The function of G-MDSCs was obviously upregulated under hypoxic conditions though targeting HIF-1α, and inhibition of HIF-1α by YC-1 apparently reduced Ptv1 expression in G-MDSCs (Zheng et al., 2019). Owing to the diverse phenotype of MDSCs, MDSCs tend to be classified into CD11b+Ly6G^Ly6C^low polymorphonuclear MDSCs (PMN-MDSCs) and CD11b^Ly6G^Ly6C^hi monocytes MDSCs (M-MDSCs) in mice (Youn et al., 2008). A latest study revealed that LncRNA AK036396 had a fairly high level of expression in PMN-MDSCs, whereas knockdown of AK036396 repressed Arg1 expression (Sun et al., 2020). A later study revealed that LncRNA AK036396 could interact with Fcnb through abrogating its ubiquitination to enhance its stability in the cytoplasm of myeloid cells, to enhance the immunosuppression of PMN-MDSCs (Sagiv et al., 2015). At the mechanistic level, the researchers found that LncRNA AK036396 could interact with Fcnb through abrogating its ubiquitination to enhance its stability in the cytoplasm of myeloid cells, to enhance the immunosuppression of PMN-MDSCs and attenuate Th1/CTL cells responses, and ultimately accelerating tumor progression (Tian et al., 2020). These studies have demonstrated that LncRNAs play a significant role in the aggregation and activation of MDSCs. However, the role and regulatory mechanism during tumor progression of these LncRNAs within MDSCs in lung cancer awaits further exploration.

**Treg Cells**

Regulatory T cells (Tregs), as a major subset of infiltrating CD4+ T cells in TME, specifically express the master transcription factor FOXP3 (Sakaguchi et al., 2020), and have been found to suppress anti-tumor immune responses in diverse ways, including: 1) targeting TGF-β, thus inhibits the anti-tumor effects promoted by CD4+ T cells, CD8+ cells, and NK cells (Konkel and Chen, 2011; Sun et al., 2020); 2) disrupting metabolism by scavenging cytokines such as IL-2, or producing immunosuppressive adhershakes by extracellular enzymes CD39 and CD73 (Spolski et al., 2018); 3) inhibiting the maturation and function of DC; 4) dissolved by granule A or B and perforation induced CD8+ lymphocytes. Several studies involving humans and mice have shown that extrinsic tissue and tumors in different tissues contain the largest Tregs, and that the absence of Tregs can significantly improve anti-tumor immunity. A few studies reported that LncRNA affects tumor progression by regulating the biological behaviors and function of T effector cells. Sun et al. identified a novel LncRNA, LINC00301, that can promote the accumulation of Tregs and decrease CD8+ T cell in NSCLC upon targeting TGF-β1 (Sun et al., 2020). Moreover, LncRNA C5orf64 expression is positively correlated with NSCLC survival, but negatively associated with Tregs levels (Pang et al., 2021).

**THE ROLE OF LncRNA IN CANCER-ASSOCIATED FIBROBLASTS**

Cancer-associated fibroblasts (CAFs), as one of major components in TME that derive from the differentiation of quiescent fibroblasts by activation of various external factors like cytokines/chemokines, growth factors, hypoxia factors, LncRNAs and so on, participate in the entire cancer developmental process, from tumor initiation to progression, including carcinogenesis, proliferation, migration, EMT, drug resistance, metabolic reprogramming, angiogenesis and immunosuppression (Wu et al., 2017; Shoucair et al., 2020; Yang et al., 2021). Growing studies also reveal that LncRNAs also play a nonnegligible role in cancer cells and CAFs by shuttling via exosomes and directly within CAFs or cancer cells. But, the roles of LncRNAs in CAFs during lung cancer progression indeed remain unclear and are poorly studied. Teng et al. had attempted to identify differentially expressed LncRNAs between CAFs and normal fibroblasts in NSCLC using LncRNA profiling analysis with the intention of selecting important biomarkers working in TME. They found that upregulated LncRNAs were involved in important cancer-related regulatory pathways such as NOD-like receptor signaling (Teng et al., 2019). The roles and mechanisms of action of individual LncRNAs in CAFs of lung cancer are starting to be realized.

**THE TUMOR VASCULATURE IS SUPPORTED BY LncRNAs**

In physiological environment, angiogenesis maintains a relatively dynamic homeostasis and is strictly controlled by pro-angiogenesis and anti-angiogenesis regulators (Ribatti et al., 2007). Hypoxia and acidosis in tumor bed are often attributed to a large consumption of oxygen and nutrients and an active metabolism under a disproportionate blood supply (Kerbel, 2008; Sun, 2012). In this case, it continues to induce the production of large amounts of pro-angiogenic factors in TME (Ronca et al., 2017). Meanwhile, various angiogenic factors such as Vascular endothelial growth factor (VEGF) (Ferrara et al., 2003), angioptin (ANGPT) (Fagiani and Christofori, 2013) and basic fibroblast growth factor (bFGF) (Zheng et al., 2018) also increase and have immunosuppressive functions. As a result, the balance of pro- and anti-angiogenesis is disturbed in cancer, leading to a shift to angiogenesis and immunosuppressive microenvironment (Ribatti et al., 2007). Some evidence has shown that LncRNAs act on tumor progression by regulation of VEGF in lung cancer. A report (Chen et al., 2020) showed that LINCO0173.v1 is upregulated in lung squamous cell carcinoma (SQC) tissues and is negatively associated with SQC prognosis. Knockdown of LINCO0173.v1 suppresses VEGFA expression, thus attenuating vascular endothelial cell proliferation and migration, as well as tumorigenesis of SQC cells. Mechanistic evidence has exhibited that LINCO0173.v1 exerts these functions by sponging miR-511-5p as a ceRNA.Hou et al. (2021) reported that LncRNA EPIC1 is significantly upregulated in NSCLC tissues and cells. EPIC1 silence represses Ang2-Tie2 signaling pathway-related proteins, thereby inhibiting HUVECs (human umbilical vein endothelial cell) proliferation and channel forming abilities. LncRNA LIN00667 induces eukaryotic translation initiation factor 4A3 (EIF4A3) expression and secretion, and consequently activates the mRNA and protein levels of...
VEGFA. Therefore, LINC00667 promotes angiogenesis of NSCLC cells and consequently results in NSCLC tumor growth and metastasis (Yang et al., 2020). Knockdown of lncRNA F630028O10Rik in lung cancer increases VEGFA and VEGFR2 expression by sponging miR-223-3p, which means that F630028O10Rik could inhibit tube formation in vascular endothelial cells, thus further influencing angiogenesis in lung cancer (Qin et al., 2020). Besides, lncRNAs, MCM3AP-AS1 (Li X. et al., 2020) and PVT1 (Mao et al., 2019) also play a key role in accelerating angiogenesis in lung cancer, respectively. These researches provide a rationale for using the anti-angiogenic effects of lncRNAs as a therapeutic option for lung cancer. Yet, the effect on tumor angiogenesis for lncRNAs still awaits further investigation.

### LncRNAs as Prognostic Biomarkers

Diagnosis and therapies using lncRNAs are being developed. For example, the investigators have conducted clinical settings to identify lncRNA biomarkers from the plasma to facilitate detection of early lung cancer (NCT03830619). Studies have suggested that lncRNAs not only interact with the TME, but closely correlate with cancer prognosis. We extracted a number of gene expression profiles of lncRNAs in Lung adenocarcinoma from the TCGA database (N = 468). Based on the best cutoff value of gene expressions, we performed Kaplan-Meier survival analysis to validate the association between part of lncRNAs mentioned above and prognosis of lung cancer using the R package "Survminer". As illustrated in Figure 2, the key lncRNAs exhibit good performance in prognostic prediction of lung cancer (p < 0.05). For instance, FDG5-AS1, HOTAIR, NKILA and LINC00662 are regarded as risk factors for survival of lung cancer (Liu et al., 2015; Gong et al., 2018; Huang et al., 2018; Lv et al., 2021), while C5orf64, DHR54-AS1 and FOXF1-AS1 are protective factors. These genes have important effects on lung cancer (Miao et al., 2016; Yan et al., 2020; Pang et al., 2021). As far as these lncRNAs are concerned, although there is no specific clinical application in lung cancer to date, they are still potential for the comprehensive treatment and diagnosis of lung cancer.

### Conclusion and Future Perspectives

Lung cancer is a highly malignant tumor that poses a serious threat to human health and life. There is a lack of effective means to identify early-stage lung cancer, leading to high mortality and failure of comprehensive interventions. Meanwhile, with advances in immunotherapy, the role of TME in the lung cancer diagnosis and prognostic is becoming increasingly critical. Components of TME interacting with lncRNA have been shown to contribute to immunomodulation and cancer progress. Hence, we summarized recent advancement involving lncRNA and their roles in the crosstalk between components of TME including infiltrated immune cells, CSCs, immune suppressive cells, macrophage, CAFs and part of the underlying molecular mechanisms. So far, only a small number of lncRNAs have been well elucidated in tumor-mesenchymal crosstalk, and in-depth studies are worthwhile to identify more lncRNAs and their specific biological functions and
mechanisms of involvement. A deeper understanding of the role played by lncRNAs in the tumor microenvironment may greatly facilitate further discovery of potential biomarkers and the development of novel targeted therapies for the treatment of lung cancer. To date, the pressing issue has been the in-depth and systematic elucidation of the regulatory determinant mechanism of lncRNAs.

In conclusion, the important regulatory roles of lncRNAs in the TME have been gradually described; however, the clinical applications of lncRNAs still need to be further explored. Along with further research, tumor-associated lncRNAs crosstalk will open a new era of anti-tumor therapy.

REFERENCES

Abdullah, L. N., and Chow, E. K. H. (2013). Mechanisms of Chemoresistance in Cancer Stem Cells. Clin. translational Med. 2, 3. doi:10.1186/2001-1326-2-3
Ahmed Laskar, A., and Younus, H. (2019). Aldehyde Toxicity and Metabolism: The Role of Aldehyde Dehydrogenases in Detoxification, Drug Resistance and Carcinogenesis. Drug Metab. Rev. 51, 42–64. doi:10.1080/03602532.2018.1555587
Aji et al. (2015). Cancer Stem Cells: The Promise and the Potential. Semin. Oncol. 42 (1), S3–S17. doi:10.1053/j.seminoncol.2015.01.001
Atianand, M. K., and Fitzgerald, K. A. (2014). Long Non-Coding RNAs and Control of Gene Expression in the Immune System. Trends Molecular Medicine 20, 623–631. doi:10.1016/j.molmed.2014.09.002
Batista, P. J., and Chang, H. Y. (2013). Long Noncoding RNAs: Cellular Address Markers or Functional Genomic Regulators of the Immune System. Trends Immunology 35, 408–419. doi:10.1016/j.it.2014.07.005
Bender, E. (2014). Epidemiology: The Dominant Malignancy. Nature 513, S2–S3. doi:10.1038/513S2a
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J. Clinicians 68, 394–424. doi:10.3322/caac.21492
Chen, J., Liu, A., Wang, Z., Wang, B., Chai, X., Lu, W., et al. (2020). LINC00173y1 Promotes Angiogenesis and Progression of Lung Squamous Cell Carcinoma by Sponging miR-511-5p to Regulate VEGFA Expression. Mol. Cancer 19, 98. doi:10.1186/s12943-020-01127-2
Chen, Z., Chen, Z., Xu, S., and Zhang, Q. (2021). LncRNA SOX2-OT/mir-30d-5p/PDK1 Regulates PD-L1 Checkpoint through the mTOR Signaling Pathway to Promote Non-Small Lung Cell Cancer Progression and Immune Evasion. Front. Genet. 12, 674856. doi:10.3389/fgene.2021.674856
Clarke, M. F., and Fuller, M. (2006). Stem Cells and Cancer: Two Faces of Eve. Cell 124, 1111–1115. doi:10.1016/j.cell.2006.03.011
Condeelis, J., and Pollard, J. W. (2006). Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis. Cell 124, 263–266. doi:10.1016/j.cell.2006.01.007
Du, Z., Niu, S., Wang, J., Wu, J., Li, S., and Yi, X. (2021). SChLAP1 Contributes to Non-Small Lung Cancer Cell Progression and Immune Evasion through Regulating the AUFI/PD-L1 Axis. Autoimmunity 54, 1–9. doi:10.1080/08916934.2021.1931582
Duan, J., Pan, Y., Yang, X., Zhong, L., Jin, Y., Xu, J., et al. (2020). Screening of T Cell-Related Long Noncoding RNA-MicroRNA-mRNA Regulatory Networks in Non-Small-Cell Lung Cancer. Biomed. Research International 2020, 1–13. doi:10.1155/2020/5816763
Fagiani, E., and Christofori, G. (2013). Angiopoietins in Angiogenesis. Cancer Lett. 328, 18–26. doi:10.1016/j.canlet.2012.08.018
Ferrara, N., Gerber, H. P., and LeCouter, J. (2003). The Biology of VEGF and its Receptors. Nat. Med. 9, 669–676. doi:10.1038/nrn1063-669
Fu, W., Zhao, J., Hu, W., Dai, L., Jiang, Z., Zhong, S., et al. (2021). LINC01224/ZNF91 Promote Stem Cell-Like Properties and Drive Radioreistance in Non-Small Cell Lung Cancer. Cancer Manag. Res. 13, 5671–5681. doi:10.2147/cmr.s313744

AUTHOR CONTRIBUTIONS

SD, TL and Y-Y L collated the data and wrote the manuscript. YH, TL, and ZK provided helpful discussion. Z-ZW and FL reviewed the manuscript. All authors reviewed the manuscript.

FUNDING

This study was supported by the Science and Technology Department of Sichuan Province (2018Y0389, 2019YFS0443).
Joyce, J. A., and Pollard, J. W. (2009). Microenvironmental Regulation of Metastasis. Nat. Rev. Cancer 9, 239–252. doi:10.1038/nrc2618

Kerbel, R. S. (2008). Tumor Angiogenesis. N. Engl. J. Med. 358, 2039–2049. doi:10.1056/NEJMra0706596

Konkel, J. E., and Chen, W. (2011). Balancing Acts: The Role of TGF-β in the Mucosal Immune System. Trends Mol. Med. 17, 668–676. doi:10.1016/j.molmed.2011.07.002

Li, S., and Lin, L. (2021). Long Noncoding RNA MCF2L-AS1 Promotes the Cancer Stem Cell-Cell-Traits in Non-Small Cell Lung Cancer Cells through Regulating miR-873-5p Level. Environ. Toxicol. 36, 1457–1465. doi:10.1007/s10641-021-03826-8

Li, S., and Lin, L. (2021). Long Noncoding RNA MCF2L-AS1 Promotes the Cancer Stem Cell-Cell-Traits in Non-Small Cell Lung Cancer Cells through Regulating miR-873-5p Level. Environ. Toxicol. 36, 1457–1465. doi:10.1007/s10641-021-03826-8

Liu, M.-Y., Li, X.-Q., Gao, T.-H., Cui, Y., Ma, N., Zhou, Y., et al. (2016). Elevated Miro-1b and Its Target Gene Mitf Promote Angiogenesis of Non-Small Cell Lung Cancer. J. Thorac. Dis. 8, 1357–1367. doi:10.7150/jtd.6346

Luo, L.-H., Xie, Y.-C., and Liu, X.-L. (2020). Long Non-coding RNA RBPAP1-AS1 Induces Lung Adenocarcinoma Migration and Vasculogenic Mimicry through Directly Binding YBX1. Mol. Cancer 17, 167. doi:10.1186/s12943-019-1102-3

Mao, Z., Xu, B., He, L., and Zhang, G. (2019). PVT1 Promotes Angiogenesis by Regulating miR-223-3p. J. Cell Mol Med. 23, 3549–3559. doi:10.1111/jcmm.15044

Miao, F., Chen, J., Shi, M., Song, Y., Chen, Z., and Pang, L. (2019). LncRNA NEAT1 Interacted With DNMT1 to Regulate Malignant Phenotype of Lung Cancer Patients. J. Thorac. Dis. 11, 8171–8182. doi:10.21037/jtd.2019.09.57

Mun, L. L., and Jain, R. K. (2019). Vascular Regulation of Antitumor Immunity. Science 365, 544–545. doi:10.1126/science.aaw7875

Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., et al. (2007). Altered Recognition of Antigen Is a Mechanism of CD8+ T Cell Tolerance in Cancer. Nat. Med. 13, 828–835. doi:10.1038/nm1609

Nasim, F., Sabath, B. F., and Eapen, G. A. (2019). Lung Cancer. Med. Clin. North America 103, 463–473. doi:10.1016/j.mcna.2018.12.006

Pang, Z., Chen, X., Wang, Y., Wang, Y., Yan, T., Wan, J., et al. (2021). Long Noncoding RNA C3orf64 Is a Potential Indicator for Tumor Microenvironment and Mutation Pattern Remodeling in Lung Adenocarcina. Genomics 113, 291–304. doi:10.1016/j.jgyge.2020.12.010

Papaoioannou, N. E., Beniata, O. V., Vitsos, P., Tsiatsilou, O., and Samara, P. (2016). Harnessing the Immune System to Improve Cancer Therapy. Ann. Transl. Med. 4, 261. doi:10.21037/atm.2016.04.01

Pardoll, D. M. (2012). The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat. Rev. Cancer 12, 252–264. doi:10.1038/nrc3329

Peng, Z., Wang, J., Shan, B., Li, B., Peng, W., Dong, Y., et al. (2018). The Long Noncoding RNA LINC00312 Induces Lung Adenocarcinoma Migration and Vasculogenic Mimicry through Directly Binding YBX1. Mol. Cancer 17, 167. doi:10.1186/s12943-019-0920-z

Qin, L., Zhong, M., Adah, D., Qin, L., Chen, X., Ma, C., et al. (2020). A Novel Tumour Suppressor lncRNA F6300280O1Rk Inhibits Lung Cancer Angiogenesis by Regulating miR-223-3p. J. Cell Mol Med. 24, 3549–3559. doi:10.1111/jcmm.15044

Ribatti, D., Nico, B., Crivellato, E., Roccacio, A. M., and Vacca, A. (2007). The History of the Angiogenic Switch Concept. Leukemia 21, 44–52. doi:10.1038/sj.lie.2104602

Ronca, R., Benkheil, M., Mitola, S., Struyf, S., and Liekens, S. (2017). Tumor Angiogenesis Revisited: Regulators and Clinical Implications. Med. Res. Rev. 37, 1231–1274. doi:10.1111/medr.201425

Sagiv, J. Y., Michaeli, J., Assi, S., Mishalhan, L., Kisos, H., Levy, L., et al. (2015). Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer. Cell Rep. 10, 562–573. doi:10.1016/j.celrep.2014.12.039

Sakaguchi, S., Yokota, N., Wing, J. B., Tanaka, A., Ichiyama, K., and Okhura, N. (2020). Regulatory T Cells in Human Disease. Annu. Rev. Immunol. 38, 541–566. doi:10.1146/annurev-immunol-042718-041717

Schoenfeld, A. J., and Hellmann, M. D. (2020). Acquired Resistance to Immune Checkpoint Inhibitors. Cancer cell 37 (4), 443–455. doi:10.1016/j.jccc.2020.03.017

Schwerdtfeger, M., Desiderio, V., Kobold, S., Regad, T., Zappavigna, S., and Caraglia, M. (2021). Long Non-Coding RNAs in Cancer Stem Cells. Translational Oncol. 14, 101134. doi:10.1016/j.tranon.2021.101134

Serafini, P., Magrobroff, S., Noonan, K., and Borrello, I. (2008). Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells. Cancer Res. 68, 5439–5449. doi:10.1158/0008-5472.can-07-6621

Shoucair, I., Weber Mello, F., Jabalée, J., Maleki, S., and Garnis, C. (2020). The Role of Cancer-Associated Fibroblasts and Extracellular Vesicles in Tumorogenesis. Int. J. Mol. Sci. 21, 6837. doi:10.3390/ijms21116837

Siegel, R. L., Miller, K. D., and Jemal, A. (2020). Cancer Statistics, 2020. CA A Cancer J. Clin. 70, 7–30. doi:10.3322/caac.21590

Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., and Ostrand-Rosenberg, S. (2007). Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response. J. Immunol. 179, 977–983. doi:10.4049/jimmunol.179.2.977

Sládek, N. E. (2003). Human Aldehyde Dehydrogenases: Potential Pathological, Pharmacological, and Toxicological Impact. J. Biochem. Mol. Toxicol. 17, 7–23. doi:10.1002/jbt.10057

Spolski, R., Li, P., and Leonard, W. J. (2018). Biology and Regulation of IL-2: from the Interleukin-2 Receptor to IL-2-Dependent Cells. Annu. Rev. Biochem. 87, 355–573. doi:10.1146/annurev-biochem-022014.140200

Sun, C.-C., Zhu, W., Li, S.-J., Hu, W., Zhang, J., Zhuo, Y., et al. (2020). FOXC1-Mediated LINC00301 Facilitates Tumor Progression and Triggers an Immune-Suppressing Microenvironment in Non-Small Cell Lung Cancer by Regulating the HIF1α Pathway. Genome Med. 12, 77. doi:10.1186/s13073-020-00773-y

Sun, W. (2012). Angiogenesis in Metastatic Colorectal Cancer and the Benefits of Targeted Therapy. J. Hematol. Oncol. 5, 63. doi:10.1186/1756-8722-5-63

Sun, Y., and Xu, J. (2019). TCF-4 Regulated lncRNA-XIST Promotes M2 Polarization of Macrophages and Is Associated With Lung Cancer. Onco Targets Ther. 12, 8055–8062. doi:10.2147/ott.s210952
